Japanese drugmaker Takeda Pharmaceutical (TSE: 4502) has announced that it has hived off part of its pharmaceutical R&D business to form a new wholly-owned subsidiary.
In addition, the company has finished a deal to transfer part of its pharmaceutical sciences businesses to privately-held Bushu Pharmaceuticals.
Takeda says the purpose of the structural reorganization is to accelerate changes to its research and development (R&D) program, by focusing on three key therapeutic areas – oncology, gastroenterology and central nervous system, plus vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze